Home › Funds › MPM BioImpact LLC › AKTS

MPM BioImpact LLC position in AKTS

AKTIS ONCOLOGY INC · Health Care

MPM BioImpact LLC reported holding 4,835,872 shares of AKTS (AKTIS ONCOLOGY INC) in its Q2 2026 13F filing — a position valued at US$155.9M, representing 9.50% of its reported portfolio and ranking #2 among its reported holdings. MPM BioImpact LLC has disclosed AKTS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)4.84M sh
Reported value held$155.86M
Portfolio Weight9.50%
First reportedQ1 2026
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How MPM BioImpact LLC's AKTS position evolved

MPM BioImpact LLC first disclosed a stake in AKTS in Q1 2026 at 4,835,872 shares (US$86.5M). The position peaked in Q2 2026 at 4,835,872 shares, worth US$155.9M. Across 2 filings, MPM BioImpact LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 4,835,872 shares valued at US$155.9M.

Quarter by quarter

QuarterSharesValueChange
Q1 2026 4.84M $86.51M New
Q2 2026 4.84M $155.86M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AKTS and 13F data

AKTS (AKTIS ONCOLOGY INC) is a Health Care company. 121 other funds we track also report a position in AKTS — the largest reported positions include EcoR1 Capital, LLC (US$155.5M), Blue Owl Capital Holdings LP (US$99.0M), RTW INVESTMENTS, LP (US$51.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AKTS

All AKTS fund holders →

FAQ

How long has MPM BioImpact LLC held AKTS?

MPM BioImpact LLC has disclosed AKTS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is MPM BioImpact LLC's current position in AKTS?

As of Q2 2026, MPM BioImpact LLC holds 4.84M shares of AKTS (AKTIS ONCOLOGY INC), valued at $155.86M, representing 9.50% of its reported portfolio and ranking #2.

Has MPM BioImpact LLC been buying or selling AKTS?

In the latest 13F filing (Q2 2026), MPM BioImpact LLC held unchanged its position in AKTS. The position peaked in Q2 2026 at 4.84M shares.

Which other funds hold AKTS?

Other major institutional holders of AKTS include EcoR1 Capital, LLC, Blue Owl Capital Holdings LP, RTW INVESTMENTS, LP, among 121 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.